Articles, guides, and regulatory updates from our community.
A landmark 2025 BMJ network meta-analysis comparing 19 obesity drugs across 262 trials reveals key trade-offs between weight loss, side effects, and heart health.
By Peptide Association Research Team
A landmark 2026 BMJ network meta-analysis of 262 trials compares 19 obesity drugs. See what researchers found about weight loss, harms, and cardiovascular outcomes.
By Peptide Association Research Team
A major 2026 BMJ network meta-analysis compared 19 obesity drugs across 262 trials. See what the evidence shows about benefits, harms, and trade-offs.
By Peptide Association Research Team
A major 2025 BMJ network meta-analysis compared 19 obesity drugs across 262 trials. See what researchers found about benefits, risks, and tradeoffs.
By Peptide Association Research Team
A major 2025 BMJ network meta-analysis of 262 trials compares 19 obesity drugs on weight loss, safety, and cardiovascular outcomes. Here's what patients should know.
By Peptide Association Research Team
A 2026 NIDDK workshop study examines how real-world evidence can fill critical gaps in GLP-1 receptor agonist safety, effectiveness, and coverage decisions.
By Peptide Association Research Team
New research explores how GLP-1 receptor agonists affect skin biology, inflammation, wound healing, and aesthetic aging. Learn what the evidence shows.
By Peptide Association Research Team
A 2026 review in JBJS Reviews examines the evidence, safety, and antidoping implications of injectable peptides used in sports medicine and orthopaedics.
By Peptide Association Research Team
The GLP-1 revolution has rewritten the rules of obesity treatment. How incretin-based peptide therapies achieve what diet and exercise alone cannot — and what comes next.
By Peptide Association Editorial Team
A head-to-head comparison of the two leading GLP-1 receptor agonists — mechanisms of action, clinical trial data, side effects, and practical considerations for providers and patients.
By Peptide Association Editorial Team